15018752330
发表时间:2015-11-24 浏览次数:496次
Introduction
Glioblastoma multiforme (GBM) is the most common type of primary central nervous system (CNS) tumor and is noted for its short survival and poor response to chemotherapeutic agents. Adjuvant temozolomide and radiotherapy is the gold-standard treatment. Unfortunately, the relapse rate is very high, and there is no reference drug for second-line treatment.
Case Report
This report describes the case of a 58-year-old patient with a history of
hypertriglyceridemia and psoriasis who was admitted to the emergency department
after a 4-day episode of disorientation to time and place, speech disturbance,
2/5 lack of muscle strength, right hemi-temporal blindness, and motor dysphasia.
Chest, abdominal, and pelvic computed tomography was unremarkable. A brain
magnetic resonance imaging (MRI) showed an oval left parieto-occipital lesion
with the anteroposterior diameter of 27 mm, nodular contrast medium enhancement
and white matter edema. In February 2011, the lesion was resected and was
diagnosed as a WHO grade 4 GBM, with a 30% mind bomb E3 ubiquitin-ligase 1
proliferation index.
In March 2011, external radiotherapy (total dose 60
Gy, fractioned in 2 Gy/day) was started with concomitant temozolomide at 75 mg/m
2 /day, followed by temozolomide monotherapy (150 mg/m 2 for 5 days each 28 day circle in the first cycle, and 200 mg/m 2 in
the second cycle). Thereafter, an episode of gait imbalance with motor
disturbance of the right upper limb occurred.
Three months after
finishing radiotherapy, a brain MRI showed a cystic left parieto-occipital
lesion measuring 40 mm × 40 mm × 30 mm, and edema. This MRI suggested tumor
relapse [Figure 1]a.
The patient rejected surgery and chemotherapy according to the Soffietti et al. [6] regimen was started. The induction phase was fotemustine 75 mg/m 2
at day 1 and day 8 and bevacizumab 10 mg/kg at day 1 and day 15,
followed by an interval of 3 weeks, and maintenance phase: fotemustine
75 mg/m 2 and bevacizumab 10 mg/kg, every 3 weeks for two
cycles. Follow-up MRI showed post-surgical changes at the left occipital
level, without contrast enhancement, toxic left leuko-encephalopathy
post-treatment, without mass effect and with no evidence of tumor
residue [Figure 1]b.
There was a clinical response and from a radiological point of view,
the mass had disappeared and there was no contrast enhancement (Response
Assessment in Neuro-Oncology criteria were used to assess this). [7] The patient was discharged on a physiological replacement dose of corticosteroids and maintenance bevacizumab monotherapy.
In
April 2012, pulmonary thromboembolism occurred, and the bevacizumab was
withdrawn. Low molecular weight heparin treatment was initiated. Two
months later, repeat MRI showed a 2.5 cm enhancement area in the
surgical site, suggesting tumor relapse. In June 2012, fotemustine was
restarted as monotherapy at 75 mg/m 2 every 3 weeks (two
cycles). In August 2012, MRI showed tumor stabilization. In November
2012, the patient suffered bronchoaspiration and unfortunately died.
Discussion
Fotemustine is a third-generation nitrosourea with alkylating cytotoxic
activity and high lipophilicity that allows it to cross the blood-brain barrier.
It achieves therapeutic levels in the CNS and has proven antitumor activity,
either as monotherapy or in combination. Bevacizumab is a humanized monoclonal
antibody that inhibits vascular endothelial growth factor and has activity in
distinct tumors like GBM, either in monotherapy or combination with irinotecan.
The combination of these two drugs has shown promising results. Soffietti
et al. published the results of a phase II study in which
fotemustine and bevacizumab were combined according to the following scheme:
induction phase (fotemustine 75 mg/m 2 at day 1 and day 8, and
bevacizumab 10 mg/kg at day 1 and day 15); followed by an interval of 3 weeks,
and maintenance phase (fotemustine 75 mg/m 2 and bevacizumab 10
mg/kg, every 3 weeks) until tumor progression, unacceptable toxicity, or
withdrawal of consent. The combination of these two drugs showed promising
results: overall response rate was 52%, and a significant neurologic improvement
was observed in 60% of symptomatic patients. Progression-free survival at 6
months was 42.6%, and overall survival at 6 months was 75.9%. Median
progression-free survival was 5.2 months, and median overall survival was 9.1
months. Toxicity with this regimen was predictable and manageable; grade 1 or 2
appeared in the majority of patients. Neutropenia (13%), thrombocytopenia (9%),
wound dehiscence (5.5%), and deep venous thrombosis (4%) are the main grade 3
toxicities. Pulmonary embolism appeared as grade 4 toxicity in 4% of patients.
These results encouraged us to use this therapeutic regimen in our
patient.
The early initial progression, occurring shortly after the
second adjuvant temozolomide cycle, made us consider a scheme that could achieve
a high rate of disease control. The outstanding response obtained at 4 months of
treatment with fotemustine plus bevacizumab, without radiological evidence from
the pre-existing tumor mass, prompted us to continue with bevacizumab
maintenance. When this patient had received temozolomide monotherapy, he
presented with instability and vertiginous symptoms. During bevacizumab and
fotemustine therapy, the neurological symptoms disappeared. The withdrawal of
bevacizumab after 7 months of treatment, due to pulmonary thromboembolism,
caused a relapse of the disease. Nonetheless, the patient achieved stabilization
of the disease from reintroduction of fotemustine until his death due to
thromboembolic and infectious complications.
We consider this case
interesting because treatment with bevacizumab plus fotemustine achieved rapid
response, in 4 months, in a patient with rapid progression to first-line
treatment. Furthermore, it is notable because the patient responded to treatment
with fotemustine after the progression that occurred following withdrawal of
bevacizumab maintenance.
We consider that this combination scheme should
be tested in further clinical trials. Due to the promising results reported by
Soffietti et al., and confirmed by our own clinical experience,
fotemustine should be considered as rescue treatment for relapsed GBM.
References
1.Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2100-60.
2.Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
3.Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
4.Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010;28:2051-7.
5.Fabrini MG, Silvano G, Lolli I, Perrone F, Marsella A, Scotti V, Cionini L. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 2009;92:79-86.
6.Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG, Pasqualetti F, Lolli I, Castiglione A, Ciccone G, Rudà R. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol 2014;116:533-41.
7.Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, DeGroot J, Wick M, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van der Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
8.Silvani A, Lamperti E, Gaviani P, Eoli M, Fiumani A, Salmaggi A, Falcone C, Filippini G, Botturi A, Boiardi A. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 2008;87:143-51.
9.Gaviani P, Salmaggi A, Silvani A. Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients. J Neurooncol 2011;104:617-8.
10.Addeo R, Caraglia M, De Santi MS, Montella L, Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V, Genovese M, Cennamo G, Del Prete S. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol 2011;102:417-24.
11.Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
12.Reardon DA, Herndon JE 2nd, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich JN, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol 2012;107:213-21.